-
-
Overview
-
Specificity: Detects human C1s. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sutimlimab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG4 Isotype Control (IB4) [ICH2257]
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
RUO sutimlimab biosimilar is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in cold agglutinin disease to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways.
-
- Properties
- Applications
-
Overview